Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 147-153 , February 2009

Fluorine-18 labeling and biodistribution studies on peroxisome proliferator-activated receptor-γ ligands: potential positron emission tomography imaging agents

  • Byung Chul Lee

      Affiliations

    • Department of Chemistry, University of Illinois, Urbana, IL 61801, USA
    • Current address: Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, South Korea.
    • ,
  • Carmen S. Dence

      Affiliations

    • Division of Radiological Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • Haibing Zhou

      Affiliations

    • Department of Chemistry, University of Illinois, Urbana, IL 61801, USA
    • Current address: College of Pharmacy, Wuhan University, Wuhan 430072, China.
    • ,
  • Ephraim E. Parent

      Affiliations

    • Department of Chemistry, University of Illinois, Urbana, IL 61801, USA
    • ,
  • Michael J. Welch

      Affiliations

    • Division of Radiological Sciences, Washington University School of Medicine, St. Louis, MO 63110, USA
    • ,
  • John A. Katzenellenbogen

      Affiliations

    • Department of Chemistry, University of Illinois, Urbana, IL 61801, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 217 333 6310; fax: +1 217 333 7325.

Received 23 September 2008 ,Revised 24 October 2008 ,Accepted 4 November 2008.

References 

  1. Greene ME, Blumberg B, McBride OW, et al. Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995;4:281–299
  2. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 1990;347:645–650
  3. Lemberger T, Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology. Annu Rev Cell Dev Biol. 1996;12:335–363
  4. Willson TM, Cobb JE, Cowan DJ, et al. The structure–activity relationship between peroxisome proliferator-activated receptor γ agonism and the anti-hyperglycemic activity of thiazolidinediones. J Med Chem. 1996;39:665–668
  5. Kliewer SA, Lenhard JM, Willson TM, et al. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell. 1995;83:813–819
  6. Mueller E, Smith M, Sarraf P, et al. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci U S A. 2000;97:10990–10995
  7. Burstein HJ, Demetri GD, Mueller E, et al. Use of the peroxisome proliferator-activated receptor (PPAR) γ ligand troglitazone as treatment for refractory breast cancer: a Phase II study. Breast Cancer Res Treat. 2003;79:391–397
  8. Panigrahy D, Shen LQ, Kieran MW, et al. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Investig Drugs. 2003;12:1925–1937
  9. Demetri GD, Fletcher CD, Mueller E, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999;96:3951–3956
  10. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR γ. Mol Cell. 1998;1:465–470
  11. Wang X, Southard RC, Kilgore MW. The increased expression of peroxisome proliferator-activated receptor-γ1 in human breast cancer is mediated by selective promoter usage. Cancer Res. 2004;64:5592–5596
  12. Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci. 2005;26:244–251
  13. Kim S-H, Jonson SD, Welch MJ, et al. Fluorine-substituted ligands for the peroxisome proliferator-activated receptor gamma (PPARγ): potential imaging agents for metastatic tumors. Bioconjug Chem. 2001;12:439–450
  14. Lowell BB, Spiegelman BM. Towards a molecular understanding of adaptive thermogenesis. Nature. 2000;404:652–660
  15. Bookout AL, Jeong Y, Downes M, et al. Nuc recep signal atlas. www.nursa.org/10.1621/datasets.020012005;
  16. Cobb JE, Blanchard SG, Boswell EG, et al. N-(2-Benzoylphenyl)-l-tyrosine PPARgamma agonists: 3. Structure–activity relationship and optimization of the N-aryl substituent. J Med Chem. 1998;41:5055–5069
  17. Collins JL, Blanchard SG, Boswell GE, et al. N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists: 2. Structure–activity relationship and optimization of the phenyl alkyl ether moiety. J Med Chem. 1998;41:5037–5054
  18. Henke BR, Blanchard SG, Brackeen MF, et al. N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists: 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J Med Chem. 1998;41:5020–5036
  19. Willson TM, Brown PJ, Sternbach DD, et al. The PPARs: from orphan receptors to drug discovery. J Med Chem. 2000;43:527–550
  20. Mathews WB, Foss CA, Stoermer D, et al. Synthesis and biodistribution of (11)C-GW7845, a positron-emitting agonist for peroxisome proliferator-activated receptor-{gamma}. J Nucl Med. 2005;46:1719–1726
  21. Young PW, Buckle DR, Cantello BCC, et al. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for peroxisomal proliferator-activated receptor γ. J Pharmacol Exp Ther. 1998;284:751–759
  22. Lee BC, Lee KC, Lee H, et al. Strategies for the labeling of halogen-substituted peroxisome proliferator-activated receptor gamma ligands: potential positron emission tomography and single photon emission computed tomography imaging agents. Bioconjug Chem. 2007;18:514–523
  23. Lee BC, Lee KC, Lee H, et al. Synthesis and binding affinity of a fluorine-substituted peroxisome proliferator-activated gamma (PPARgamma) ligand as a potential positron emission tomography (PET) imaging agent. Bioconjug Chem. 2007;18:507–513
  24. Koser GF, Wettach RH, Smith CS. New methodology in iodonium salt synthesis. Reactions of [hydroxy(tosyloxy)iodo]arenes with aryltrimethylsilanes. J Org Chem. 1980;45:1543–1544
  25. Pike VW, Butt F, Shah A, et al. Facile synthesis of substituted diaryliodonium tosylates by treatment of aryltributylstannanes with Koser's reagent. J Chem Soc Perkin Trans. 1999;1:245–248
  26. Shah A, Pike VW, Widdowson DA. Synthesis of [18F]fluoroarenes from the reaction of cyclotron-produced [18F]fluoride ion with diaryliodonium salts. J Chem Soc Perkin Trans. 1998;1:2043–2046
  27. Van der Puy M. Conversion of diaryliodonium salts to aryl fluorides. J Fluorine Chem. 1982;21:385–392
  28. Clement J-B, Hayes JF, Sheldrake HM, et al. Synthesis of SB-214857 using copper catalyzed amination of aryl bromides with l-aspartic acid. Synlett. 2001;1423–1427
  29. Ma D, Zhang Y, Yao J, et al. Accelerating effect induced by the structure of α-amino acid in the copper-catalyzed coupling reaction of aryl halides with α-amino acids. Synthesis of benzolactam-V8. J Am Chem Soc. 1998;120:12459–12467
  30. Xu L-W, Xia CG, Li JW, et al. Efficient palladium/copper-cocatalyzed C–N coupling reaction of unactivated aryl bromide or iodide with amino acid under microwave heating. Catal Commun. 2004;5:121–123
  31. Sharp TL, Dence CS, Engelbach JA, et al. Techniques necessary for multiple tracer quantitative small-animal imaging studies. Nucl Med Biol. 2005;32:875–884

PII: S0969-8051(08)00241-2

doi: 10.1016/j.nucmedbio.2008.11.002

Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 147-153 , February 2009

Article Tools

* Image Usage & Resolution